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EDUCATIONAL OBJECTIVES
After reading this course, the participant
should be able to:
1. Define burning mouth
syndrome. 





3. List various treatments
options for patients with
burning mouth syndrome. 
4. Describe the role of dental
health care workers in




Burning mouth syndrome (BMS) is a chronic, painful condition with no clear etiology or
specific, proven treatment. BMS is also known as burning tongue syndrome, glossodynia,
glossopyrosis, stomatodynia, stomatopyrosis, and oral dysesthesia.1,2 The syndrome is
characterized by burning and/or painful sensations of the mouth, usually in the absence of
clinical or laboratory findings.3 It can occur anywhere in the mouth. However, the most
frequently affected sites are the tip and anterior two-thirds of the tongue followed by the
lower lip and hard palate.4 Patients typically report no pain in the morning with increased
discomfort as the day progresses. The prevalence rate of BMS in the general population
varies from 0.7% to 15%. It is more common in women (5.5%) than men (1.6%).5-7 
Diagnosis 
There is no clear consensus on the etiology, pathogenesis, or treatment of BMS.8 Most
patients usually consult several clinicians, often without a clear explanation or appropriate
diagnosis for their painful condition.9 Diagnosis of BMS is dependent on a detailed history
of clinical signs and symptoms; a thorough intraoral and extraoral examination; and an
assessment of local, systemic, and environmental factors. Clinical signs and symptoms of
BMS may include a burning sensation of the tongue; pain; xerostomia; sialorrhea; tongue
ulcers; dysphagia; dysgeusia; sensation of a lump in the throat; parafunctional habits,
such as bruxism and tongue thrusting; and malodor.7,10 
For some patients, there may be a link between BMS and other conditions such as
Sjögren's syndrome or fungal infections. Therefore, local, systemic, and environmental
factors need to be investigated (Table 1).11 If the cause can be identified, the disorder is
referred to as secondary BMS.10 If no cause of symptoms can be identified, the diagnosis
is primary or idiopathic BMS.10 
Etiology 
The etiology of BMS is unknown with much debate appearing in the literature, which
poses a problem for clinicians who are trying to diagnose the condition and may lead to
significant frustration for patients.12 The average patient visits approximately three
practitioners before being correctly diagnosed.9 Various systemic, local, psychogenic, and neuropathic factors are associated
with BMS. 
Systemic Factors 
Systemic conditions linked to the symptoms of BMS include menopause, diabetes, and nutritional deficiencies.12 Hormonal
changes are important factors in BMS. Women are approximately seven times more likely to be affected than men, and
approximately 90% of the women participating in BMS studies are post-menopausal.8,12 The onset of pain tends to range from
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Table 1. Clinical conditions and investigations
relevant to BMS.11 
Clinical Conditions  Investigations 
Salivary dysfunction  Sialometry, blood biochemistry  
Candidiasis Fungal culture  
Mucosal disease Biopsy (rare)  
Mucosal atrophy  Iron studies, folate, vitamin B12 





Clinical Conditions  Investigations 
3 years prior to menopause to 12 years after menopause, and BMS has been reported in 10% to 40% of women presenting for
treatment of menopausal symptoms.8,12 However, estrogen replacement therapy does not relieve pain in all cases.12 
Nutritional deficiencies—particularly in vitamins B1, B2, B6, and B12—may be present in patients who have BMS.8,12 Low
blood serum levels of iron have also been implicated.12 However, nutritional supplementation does not always provide symptom
relief.12 
There is some evidence that type 2 diabetes may contribute to the development of BMS but the correlation is still controversial.
Some researchers believe that a link exists between the type of insulin used and the symptoms of BMS, while others surmise
that complaints of burning mouth among people who have diabetes are probably caused by candidiasis.12 BMS symptoms in
these patients may also be related to neuropathy, which is a common complication of type 2 diabetes.12 
Case reports have also linked burning mouth symptoms and loss of
taste sensation to the use of angiotensin-converting enzyme inhibitors
(medications used for the treatment of hypertension and congestive
heart failure). Symptoms tend to subside within several weeks of
discontinuing these medications.8 
Local Factors 
Many local conditions have been implicated in symptoms of BMS
including: candidiasis, lichen planus, xerostomia, allergic reactions, geographic tongue, recent dental treatment, and galvanic
currents between dissimilar metals.8,12,13 Some local factors that show stronger evidence include local nerve trauma, oral
parafunctional habits, and salivary gland dysfunction.12 
Peripheral nerve in - jury may play a role in the symptoms of BMS because
the symptoms show a pattern similar to those observed in some
inflammatory neural conditions.12 Several studies also suggest that
parafunctional habits, such as tongue thrusting, bruxism, and clenching,
are more common in patients who have BMS.12,13 These activities are
often related to anxiety, which is more prevalent in patients who have
BMS.10,12 
Patients who have BMS experience a higher incidence of xerostomia,
therefore, salivary gland dysfunction is suspected to play a role in the
symptoms.8,12 Reduction in salivary flow may be due to radiation therapy,
systemic disease, or side effects of different medications.12 Candidiasis
has also been proposed as a cause of BMS, and while it can cause burning
pain, it is not more prevalent in patients who have BMS.8 
Psychogenic Factors 
Evidence suggests that many BMS patients show signs of psychological problems, including mood changes, anxiety,
depression, personality disorders, and an increased tendency toward somatization (the chronic and persistent complaint of
physical symptoms that have no identifiable etiology) leading some researchers to believe that psychogenic factors may lead to
BMS.10,13 However, these symptoms may be secondary to living in chronic pain and the frustration of visiting one practitioner
after another, rather than the cause of BMS. Psychological problems are common in patients who experience chronic pain.8,10
In one study, patients who had BMS reported adverse life events more frequently, such as having a difficult childhood, poor
adaptation to school and work, loss of a loved one, divorce, retirement, or difficulty in understanding, processing, or describing
emotions (alexithymia).13 
Neuropathy 
Patients with BMS often exhibit taste changes and sensory dysfunctions, suggesting that there may be a neuropathic basis to
the condition.12 An underlying disorder of the autonomic innervation of the oral cavity may be present, leading to abnormal pain
perception, raised trigeminal nerve sensitivity, alterations in nerve transmission, and disturbances of the mucosal neurovascular
microcirculatory system.12 
More than two-thirds of patients who have BMS complain of altered taste sensation, often described as a spontaneous metallic
taste.14 Results of a 2007 study suggest that BMS may be a form of neuropathic pain related to dysfunction of the chorda
tympani nerve, which is responsible for taste sensation in the anterior two-thirds of the tongue.13 
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Glossary of Terms  
Alexithymia: a clinical feature common in
posttraumatic stress disorder characterized by the
inability to identify and articulate feelings
 Dysesthesia: abnormal sensations of the mouth,
such as a feeling of numbness, tingling, prickling, or
burning
 Dysgeusia: impairment or perversion of taste so that
normal tastes are interpreted as being unpleasant or
completely different from the characteristic taste of a
particular food
 Dysphagia: inability to or difficulty in swallowing
 Glossodynia: pain in the tongue
 Glossopyrosis: a burning sensation of the tongue
 Neuropathy: disorders of the nerves of the
peripheral nervous system
 Sialorrhea: excessive secretion of saliva
 Stomatodynia: pain in the mouth
 Stomatopyrosis: a burning sensation in the mouth 
Source: Venes D, ed. Taber's Cyclopedic Medical Dictionary.
19th ed. Philadelphia: F.A. Davis Co; 2001. 
Treatment 
Successful treatment of BMS is dependent on a number of factors
including ascertaining a correct diagnosis followed by diagnosis
confirmation, patient acceptance and understanding of the likely clinical
course, and patient participation in the development of a treatment
strategy.11 Patient compliance and feedback during treatment and the
ongoing interest of the clinician are also important.11 
Treatment options vary from no treatment (the most common) to physical
therapy to laser therapy (seldom used).11 Pharmaceuticals such as anti-
anxiety drugs and antidepressants are often prescribed. Tricyclic
antidepressants in particular have proven helpful for some patients but not
all.11 Other treatments include topicals, such as capsaicin; relaxation
programs; exercise programs; alternative medications, such as alpha-lipoic
acid; formal psychotherapy; cognitive behavior therapy; and alternative
therapies, such as acupuncture and massage.11 
Although only a limited number of properly constructed treatment trials
have been conducted, treatments proven effective in controlled double-
blind studies are cognitive behavior therapy; clonazepam, an
anticonvulsant and muscle relaxant used either topically or systemically;
and the nutritional supplement alpha-lipoic acid, which is a fatty acid found
naturally inside every cell in the body that produces energy for the body's everyday functions.11 One study found that 11 out of
31 patients reported benefit from taking 600 mg per day of alpha-lipoic acid in divided doses.15 However, this study was not a
randomized, controlled, double-blind study, but rather subjective follow-up collected through phone surveys. A randomized,
double-blind, placebo-controlled trial evaluated the effects of taking the plant species Hypericum perforatum extract or St.
John's Wort systemically in patients who have BMS and found no significant difference between patients who received a
placebo and those who received the extract.16 
A Cochrane Review looked at nine trials including the interventions of alpha-lipoic acid (three trials), anticonvulsants (one trial),
antidepressants (two trials), cognitive behavior therapy (one trial), analgesics (one trial), and hormone replacement therapy
(one trial).5 Only three interventions demonstrated a reduction in BMS symptoms: alpha-lipoic acid, the anticonvulsant
clonazepam, and cognitive behavior therapy.5 The Cochrane Review concluded there is insufficient evidence to show the effect
of pain killers, hormones, or antidepressants in treating BMS but there is some evidence that learning to cope with the disorder,
anticonvulsants, and alpha-lipoic acid may help.5 
Dental Practice Considerations 
Addressing BMS has implications for all members of the dental team and includes individualized assessment and treatment;
empathy; palliative care; treatment of underlying factors, such as xerostomia; and helping patients learn to cope. The daily
prescription of .25 mg to 2 mg of clonazepam may be considered for short-term relief of pain. Patients should be prescribed the
lowest dose initially with the dose then increasing by .25 mg per day until burning is relieved or side effects occur. As the
dosage increases, the medication should be taken in three divided doses.8 Recommending an alpha-lipoic acid supplement
may also be considered. The dose is 200 mg three times a day to be taken with food.17 If candidiasis is present, an anti-fungal
should be prescribed. 
After the medical history is reviewed, the dental hygienist should follow-up on medications the patient may be taking in
relationship to BMS. Morning appointments may work best for patients because the pain increases as the day progresses. A
thorough intraoral exam may reveal xerostomia, candidiasis, and/or possible signs of allergic hypersensitivity to dental
materials. 
The traditional treatment considerations for xerostomia are appropriate for patients who have BMS, including mechanical
salivary stimulation through the use of sugarless gums and lozenges,18,19 saliva substitutes,18,20 mouth rinses, and other
products made specifically for dry mouth.18 Strategies such as adequate hydration and taking frequent sips of water;19 using a
cool air humidifier, particularly at night;19 using home fluorides, such as a prescription strength gel and toothpastes with 5,000
ppm;20 changing patients' medication regimen; and prescribing medications for the relief of dry mouth, such as pilocarpine or
cevimeline, may be helpful.18-20 Further recommendations include avoiding the use of mouthrinses and beverages containing
alcohol, avoiding overly salted foods, avoiding foods and drinks high in sugar, and encouraging the practice of meticulous oral
hygiene.20 
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The dental office may want to develop a referral list of other health care providers who can assist patients with nutritional
assessment, behavioral modification, and alternative therapies to treat BMS. 
Although the etiology and treatment for BMS is challenging for clinicians and frustrating for patients, the dental team is integral
to helping patients cope with this painful oral syndrome. 
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